Human CD4+CCR6+CD161+ T cells from healthy donors or synovial cells from RA patients were cultured in Iscove’s modified Dulbecco’s medium with KnockOut Serum Replacement (both from Life Technologies) for 6 days in the presence of Human T Cell Activator CD3/CD28 Dynabeads (Life Technologies). IL-1β, IL-6, IL-23, and transforming growth factor–β (TGF-β1) (all at 10 ng/ml) were added on the first day of culture. On day 3, IL-2 (0.5 U/ml) and IL-23 were added. All cytokines were supplied by PeproTech, except IL-23, which was obtained from R&D Systems. Synovial tissue biopsies were obtained from RA patients undergoing joint replacement surgery after written informed consent was received.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.